Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359354 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MAP3K5NOTUMRAB9AKEAP1 | |
| SCHEMBL4559009 | 0.75 | NOTUM (0.42) | MAP3K5NOTUMKEAP1 | |
| SCHEMBL30643761 | 0.75 | NOTUM (0.42) | MAP3K5NOTUMKEAP1 | |
| SCHEMBL2572956 | 0.74 | EGLN2 (0.67) | EGLN1ALDH1A1GAA | |
| SCHEMBL31078777 | 0.73 | NOTUM (0.53) | SMN1; SMN2NOTUMRAB9AALKBH2EGLN1 | |
| SCHEMBL28191878 | 0.73 | NOTUM (0.41) | MAP3K5NOTUMKEAP1 | |
| SCHEMBL2731431 | 0.73 | NOTUM (0.53) | SMN1; SMN2NOTUMRAB9AALKBH2EGLN1 | |
| SCHEMBL24240280 | 0.73 | NOTUM (0.48) | MAP3K5NOTUMKEAP1 | |
| SCHEMBL8133334 | 0.73 | NOTUM (0.43) | NOTUMKEAP1 | |
| SCHEMBL173802 | 0.72 | KDM4E (0.50) | SMN1; SMN2NOTUMRAB9AALKBH2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-114787173-B | Metal complex | UDC爱尔兰有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-116173989-B | High 1T-MoS2Preparation and performance research of dissimilar metal colorimetric sensor material | 哈尔滨理工大学 | 2024-06-11 | — | — | CN | claimed |
| CN-117466341-A | Polyacid-induced hollow CoS 2 Preparation and application of nanospheres | 哈尔滨理工大学 | 2024-01-30 | — | — | CN | claimed |
| CN-114591354-B | Production and preparation method of 4-hydroxy-1, 5-naphthyridine europium complex | 兰州睿尔思新材料有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-114805836-B | Preparation and catalytic performance of polyacid-based cobalt organic framework with double interpenetrating structure | 哈尔滨理工大学 | 2023-09-08 | — | — | CN | claimed |
| CN-114790298-B | Multi-acid-base nickel metal organic frame colorimetric sensing material with interpenetrating structure | 哈尔滨理工大学 | 2023-07-04 | — | — | CN | claimed |
| CN-116173989-A | High 1T-MoS 2 Preparation and performance research of dissimilar metal colorimetric sensor material | 哈尔滨理工大学 | 2023-05-30 | — | — | CN | claimed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | claimed |
| CN-114805836-A | Preparation and catalytic performance of polyacid-based cobalt organic framework with double interpenetrating structure | 哈尔滨理工大学 | 2022-07-29 | — | — | CN | claimed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | claimed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| WO-2009054789-A1 | 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| WO-2009054785-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| EP-1613617-A4 | DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007059457-A2 | INDICATOR FIXED ION-EXCHANGE MEMBRANE | ADVANCED ENERGY TECHNOLOGY INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-1613617-A2 | DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089306-A2 | DI-ARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | claimed |
| US-4775762-A | INSECTICIDES | THE DOW CHEMICAL COMPANY (US) | 1988-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | SMN1; SMN2 4259/4885MAP3K5 4383/4885NOTUM 2634/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | SMN1; SMN2 905/4885MAP3K5 2535/4885NOTUM 1507/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | SMN1; SMN2 905/4885MAP3K5 2535/4885NOTUM 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.